Creative Planning
MYGN icon

Creative Planning’s Myriad Genetics MYGN Stock Holding History

Creative Planning’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,000
Closed -$5K – 4281
2014
Q3 		$5K Hold
2,000
– – ﹤0.01% 3300
2014
Q2 		$9K Buy
+2,000
New +$74.4K ﹤0.01% 2934

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Creative Planning's MYGN Position: Q2 2026 in Review

Creative Planning increased its Myriad Genetics (MYGN) stake by 4.6% in Q2 2026, buying an estimated $14.8K and bringing the position to 73,505 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

Creative Planning first reported a position in MYGN in Q2 2013 and has held it in 32 quarters since. The position peaked at $562K in Q3 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Creative Planning held 73,505 shares of Myriad Genetics worth $420K as of Q2 2026.
  • Creative Planning bought 3,264 Myriad Genetics shares in Q2 2026, an estimated $14.8K.
  • Myriad Genetics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3317 holding.
  • Creative Planning first reported a position in Myriad Genetics in Q2 2013 and has held it in 32 quarters since.
  • Creative Planning's Myriad Genetics position peaked at $562K in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.